News
AMRN
0.8601
-2.11%
-0.0185
12 Health Care Stocks Moving In Wednesday's After-Market Session
Acrivon Therapeutics stock rose 12.3% to $10.67 during Wednesday's after-market session. The company's, Q1 earnings came out today. Amarin Corp stock moved upwards by 8.12% and Universe Pharmaceuticals stock rose 7.47% in the same session.
Benzinga · 1d ago
Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event
Petition filed with the FDA to address significant off-label prescribing of fenofibrates. The filing comes as heart disease continues to be the leading cause of death in the United States. Amarin Corporation plc has no clinical benefit when used in combination with statins to reduce cardiovascular disease risk.
Barchart · 1d ago
Amarin Shareholders Show Strong Support at Annual Meeting
TipRanks · 3d ago
Weekly Report: what happened at AMRN last week (0415-0419)?
Weekly Report · 3d ago
Amarin Corporation: Small Signs Of Recovery May Not Be Enough
Home Healthcare Amarin Corporation: Small Signs Of Recovery May Not be Enough. Amarin is going through a turbulent period with a contraction in revenue and margins. The EU and China markets seem too small to make significant changes. The US market is suffering from margin erosion. The number of hedge funds that are investing in Amarin plc is reducing.
Seeking Alpha · 04/16 17:51
Weekly Report: what happened at AMRN last week (0408-0412)?
Weekly Report · 04/15 09:51
Weekly Report: what happened at AMRN last week (0401-0405)?
Weekly Report · 04/08 09:53
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24
Amarin Corporation plc highlighted three data presentations at ACC.24 showcasing the mechanistic activity of Eicosapentaenoic acid (EPA) Three data presentations highlight potential effects of EPA on endothelial cell dysfunction and on oxidation of samples enriched with Lp(a)
Barchart · 04/08 07:00
New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
Barchart · 04/06 14:30
Amarin (AMRN) Up 7% on Intellectual Property Wins in Europe
NASDAQ · 04/04 17:20
BRIEF-Amarin Provides Update On VAZKEPA (Icosapent Ethyl) Intellectual Property Portfolio In Europe
Amarin Provides Update On VAZKEPA (Icosapent Ethyl) Intellectual Property Portfolio In Europe. Amarin to grant Europe's Patent Office for new patent covering the chemical. The company plans to extend the exclusive rights to the chemical into 2039.
Reuters · 04/03 12:52
AMARIN- GOT DECISION TO GRANT FROM EUROPEAN PATENT OFFICE FOR NEW PATENT COVERING VAZKEPA,EXTENDING VAZKEPA EXCLUSIVITY 8 ADDITIONAL YEARS INTO 2039
Reuters · 04/03 12:00
Weekly Report: what happened at AMRN last week (0325-0329)?
Weekly Report · 04/01 09:52
Amarin Announces Research Evaluating Benefits Of VASCEPA/VAZKEPA To Be Presented At The American College Of Cardiology's Annual Scientific Session & Expo
Subgroup Analyses from the landmark REDUCE-IT outcomes trial and mechanistic data on Icosapent Ethyl will be presented at the American College of Cardiology's Annual Scientific Session & Expo, April 6 – 8, 2024 in Atlanta, GA. Amarin's VASCEPA/VAZKEPA will be featured at the meeting.
Benzinga · 03/25 12:22
Weekly Report: what happened at AMRN last week (0318-0322)?
Weekly Report · 03/25 09:54
Weekly Report: what happened at AMRN last week (0311-0315)?
Weekly Report · 03/18 09:53
Weekly Report: what happened at AMRN last week (0304-0308)?
Weekly Report · 03/11 09:52
Weekly Report: what happened at AMRN last week (0226-0301)?
Weekly Report · 03/04 09:53
Amarin's (AMRN) Q4 Earnings and Revenues Surpass Estimates
NASDAQ · 03/01 14:30
Validea Kenneth Fisher Strategy Daily Upgrade Report - 3/1/2024
NASDAQ · 03/01 11:05
More
Webull provides a variety of real-time AMRN stock news. You can receive the latest news about Amarin through multiple platforms. This information may help you make smarter investment decisions.
About AMRN
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.